A5053933311- Clinical Nutrition and Gastroenterology
- Diet and metabolism studies
- Pancreatitis Pathology and Treatment
- Gut microbiota and health
- Nutrition and Health in Aging
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Nutritional Studies and Diet
- Renal cell carcinoma treatment
- Melanoma and MAPK Pathways
- Endometrial and Cervical Cancer Treatments
- Colorectal Cancer Screening and Detection
- Liver Disease Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Synthesis and biological activity
- Pancreatic and Hepatic Oncology Research
- Digestive system and related health
- Abdominal Surgery and Complications
- Helicobacter pylori-related gastroenterology studies
- Electrolyte and hormonal disorders
- Cancer Genomics and Diagnostics
- Child Nutrition and Feeding Issues
- Metabolism and Genetic Disorders
- Ovarian cancer diagnosis and treatment
- Economic and Financial Impacts of Cancer
University of Pittsburgh
2016-2025
Merck & Co., Inc., Rahway, NJ, USA (United States)
2014-2024
Stellenbosch University
2019-2024
Moorabbin Hospital
2024
European Institute of Oncology
2021-2024
Florida Cancer Specialists & Research Institute
2024
University of Milano-Bicocca
2024
University of Pittsburgh Medical Center
2006-2023
UPMC Presbyterian
2020-2022
Presbyterian Hospital
2020-2022
Rates of colon cancer are much higher in African Americans (65:100,000) than rural South Africans (<5:100,000). The rates associated with animal protein and fat, lower fibre consumption, colonic secondary bile acids, short-chain fatty acid quantities mucosal proliferative biomarkers risk otherwise healthy middle-aged volunteers. Here we investigate further the role fat this association. We performed 2-week food exchanges subjects from same populations, where were fed a high-fibre, low-fat...
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with without bevacizumab.
<h3>Background and aims</h3> Teduglutide, a GLP-2 analogue, may restore intestinal structural functional integrity by promoting repair growth of the mucosa reducing gastric emptying secretion, thereby increasing fluid nutrient absorption in patients with short bowel syndrome (SBS). This 24-week placebo-controlled study evaluated ability teduglutide to reduce parenteral support SBS failure. <h3>Methods</h3> In 83 randomised receive subcutaneous 0.10 mg/kg/day (n=32), 0.05 (n=35) or placebo...
BackgroundPatients with castration-resistant prostate cancer derive only modest clinical benefit from available therapies. Blockade of the inhibitory programmed death 1 (PD-1) receptor by monoclonal antibodies has been effective in several malignancies. Results adenocarcinoma cohort nonrandomized phase Ib KEYNOTE-028 trial pembrolizumab advanced solid tumors are presented.Materials and methodsKey eligibility criteria included adenocarcinoma, unsuccessful standard therapy, measurable disease...
Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear.
In this consensus statement, an international panel of experts deliver their opinions on key questions regarding the contribution human microbiome to carcinogenesis.International in oncology and/or research were approached by personal communication form a panel. A structured, iterative, methodology based around 1-day roundtable discussion was employed derive expert microbiome-oncology research.Some 18 convened for and five identified regarding: (1) relevance dysbiosis/an altered gut...
In the pivotal 24-week, phase III, placebo-controlled trial, teduglutide significantly reduced parenteral support (PS) requirements in patients with short bowel syndrome (SBS). STEPS-2 was a 2-year, open-label extension of that study designed to evaluate long-term safety and efficacy teduglutide.Enrolled had completed 24 weeks either (TED/TED) or placebo (PBO/TED) initial qualified for study, but were not treated (NT/TED) because full enrollment. Patients received subcutaneous 0.05 mg/kg/day...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg placebo once every 3 weeks up 35 cycles plus...
The relationship between microbiota, short chain fatty acids (SCFAs), and obesity remains enigmatic. We employ amplicon sequencing targeted metabolomics in a large (n = 1904) African origin cohort from Ghana, South Africa, Jamaica, Seychelles, the US. Microbiota diversity fecal SCFAs are greatest Ghanaians, lowest Americans, representing each end of urbanization spectrum. Obesity is significantly associated with reduction SCFA concentration, microbial diversity, synthesizing bacteria,...
The aims of this study were to define the indications for, and evaluate cost-effectiveness of, nutritional support in patients with acute pancreatitis.All admissions during 12-month period from January through December 2000, entered into a common management protocol consisting an initial 48-h fast i.v. fluids analgesics. After 48 h, those who improving restarted on oral feeding (group O). remaining randomized receive nasojejunal EN) or parenteral TPN). randomization was continued until 50...